Tempus AI saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 66 to 90.
IBD's proprietary rating measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the market's biggest winners tend to have an RS Rating north of 80 at the beginning of a new climb.
How To Use Stock Charts To Stay Profitable And Protected
While now is not an ideal time to jump in, see if the stock is able to offer and clear an appropriate buy point.
The company reported 0% earnings growth last quarter. Revenue gains came in at 36%.
Tempus AI holds the No. 8 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte, Natera and Medpace Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
